The company is focusing its efforts to develop human monoclonal antibodies for treatment
or protection against hepatitis C, a liver disease caused by the hepatitis C virus (HCV) and
estimated to affect 170 million people worldwide. Human antibodies against the HCV
surface proteins will be used; they have recently shown very potent and broad antiviral
effects against HCV of all known subfamilies. Patents covering the antibodies have been
granted and are fully owned by the company.